Skip to main content

Advertisement

Log in

The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Previous magnetic resonance spectroscopy (MRS) studies have shown increased myo-inositol (MI) and decreased N-acetyl aspartate (NAA) levels in the parieto-occipital lobes of patients with Alzheimer's disease (AD) compared to those with other dementias and normal subjects. This study aimed to establish the quantitative relationship between metabolite ratios and degree of cognitive impairment in patients with mild to moderate AD and sub-cortical ischaemic vascular dementia (SIVD). Forty-four older people with clinical dementia were recruited from a memory clinic and followed up for 2.0–3.5 years; 20 cases were finally classified as probable AD, 18 as SIVD and 6 as mixed type. Mini Mental State Examination (MMSE) and short echo time single voxel automated MRS from the mesial parieto-occipital lobes were performed at the time of initial referral. Spearman rank correlation coefficients were calculated for MMSE scores and measured metabolite ratios MI/Cr, NAA/Cr, Cho/Cr and NAA/MI. The AD group showed a significant correlation between MMSE and NAA/MI (r=0.54, P=0.014) and NAA/Cr (r=0.48, P=0.033), and a negative, non-significant association with MI/Cr (r=−0.41, P=0.072). MI/Cr was negatively correlated with NAA/Cr (r=−0.51, P=0.021). Neither Cho/Cr ratios nor age correlated with cognitive function. The SIVD group showed no correlation between any of the measured metabolite ratios and MMSE score. This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive impairment in AD. MRS may have a role in evaluating disease progression and therapeutic monitoring in AD, as new treatments become available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Miller BL, Moats RA, Shonk T, Ernst T, Wooley S, Ross BD (1993) Alzheimer disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 187:443–447

    Google Scholar 

  2. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer's disease; differentiation with frontal lobe H-1 MR Spectroscopy. Radiology 203:829–836

    CAS  PubMed  Google Scholar 

  3. Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neurology 56:592–598

    CAS  PubMed  Google Scholar 

  4. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, Semple J, Doddrell DM (1999) A1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17:291–299

    CAS  PubMed  Google Scholar 

  5. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack CR Jr (2002)1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 8:934–942

    Article  CAS  PubMed  Google Scholar 

  6. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y (2002) Correlation of regional proton magnetic resonance spectroscopy metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 59:995–962

    Google Scholar 

  7. Ferguson KJ, MacLullich AM, Marshall I, Deary IJ, Starr JM, Seckl JR, Wardlaw JM (2002) Magnetic resonance spectroscopy and cognitive function in healthy elderly men. Brain 25:2743–2749.

    Article  Google Scholar 

  8. McConnell JR, Chaudry M, Waldman A, Grant DS, Martin PA (1997) Brain MR Spectroscopy at 1.0 Tesla [letter]. Br J Radiol 70:867

    CAS  PubMed  Google Scholar 

  9. Waldman ADB, Rai GS, McConnell JR, Chaudry M, Grant D (2002) Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and vascular dementia in older people. Arch Gerontol Geriatr 35:137–142

    Article  Google Scholar 

  10. Folstein MF, Folstein S, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinicians. Psychiatr Res 12:189–198

    CAS  PubMed  Google Scholar 

  11. Wolf-Klein G, Brod MS, Levy AP (1987) A rapid screening test for Alzheimer's disease. Gerontologist 27:12A

    Google Scholar 

  12. Hachinski V (1985) Multi-infarct dementia. Neurol Clin1:27–36

    Google Scholar 

  13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939–944

    PubMed  Google Scholar 

  14. Stoppe G, Bruhn H, Pouwels PJ, Hanicke W, Frahm J (2000) Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis Assoc Disord 14:112–119

    Article  CAS  PubMed  Google Scholar 

  15. Antuono PG, Jones JL, Wang Y, Li SJ (2001) Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1) H MRS at 0.5T. Neurology 56:737–742.

    CAS  PubMed  Google Scholar 

  16. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289–298

    CAS  PubMed  Google Scholar 

  17. Strange K, Emma F, Paredes A, Morrison R (1994) Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 12:35–43

    CAS  PubMed  Google Scholar 

  18. Cheng LL, Newell K, Mallory AE, Hyman BT, Gonzalez RG (2002) Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 20:527–533

    Article  PubMed  Google Scholar 

  19. National Institute for Clinical Excellence, London (2001) Technology appraisal guidance no 19. Guidance on the use of donepezil, rivastigmine and gallantamine for the treatment of Alzheimer's disease.

  20. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD (1995) Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195: 65–72

    CAS  PubMed  Google Scholar 

  21. Leary SM, Brex PA MacManus DG Parker GJM Barker G Miller DH Thompson AJ (2000) A1H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis: Magn Reson Imaging 18:455–459

    Google Scholar 

  22. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease (2000) Lancet 355:1696–1697

    Article  CAS  PubMed  Google Scholar 

  23. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD (2002) Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125:2332–2341

    Article  PubMed  Google Scholar 

  24. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC (2002) Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 99:4703–4707

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The Golden Charitable Trust for financial assistance. Dr. Nick Fox at the Dementia Research Group for helpful comments on the manuscript. Mahera Chaudry, Dr. Jim McConnell and Dr. David Grant in the Department of Radiology, and members of the psychology department at the Whittington Hospital.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. D. Waldman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waldman, A.D., Rai, G.S. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiology 45, 507–512 (2003). https://doi.org/10.1007/s00234-003-1040-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-003-1040-y

Keywords

Navigation